Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
TNXP Revenue Analysis (2013–2024)
As of March 2, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) generated trailing twelve-month (TTM) revenue of $10.3 million, reflecting strong growth of +16.6% year-over-year. The most recent quarter (Q3 2025) recorded $3.3 million in revenue, up 64.7% sequentially.
Looking at the longer-term picture, TNXP's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.1 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY), TNXP has underperformed the peer group in terms of revenue growth. Compare TNXP vs BNTX →
Peer Comparison
Compare TNXP's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TNXPCurrent | $10M | +16.6% | - | -1354.3% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.1M | +29.9% | $2.3M | 23.1% | $-136,701,000 | -1354.3% |
| 2023 | $7.8M | - | $3.0M | 39.0% | $-118,380,000 | -1523.9% |
| 2022 | $0 | - | $0 | - | $-112,091,000 | - |
| 2021 | $0 | - | $0 | - | $-92,312,000 | - |
| 2020 | $0 | - | $-27,000 | - | $-50,511,000 | - |
| 2019 | $0 | - | $0 | - | $-28,828,000 | - |
| 2018 | $0 | - | $-26,322,000 | - | $-26,322,000 | - |
| 2017 | $0 | - | $-21,291,000 | - | $-21,291,000 | - |
| 2016 | $0 | - | $-38,969,000 | - | $-38,969,000 | - |
| 2015 | $0 | - | $-48,162,000 | - | $-48,162,000 | - |
See TNXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNXP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TNXP vs AGIO
See how TNXP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TNXP's revenue growth accelerating or slowing?
TNXP revenue is accelerating at +16.6% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $10M. Growth momentum has increased versus prior periods.
What is TNXP's long-term revenue growth rate?
Tonix Pharmaceuticals Holding Corp.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +16.6% is above this long-term average.
How is TNXP's revenue distributed by segment?
TNXP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.